By: Lindsey Wahlstrom-Edwards Source: antidote.me I have never been one for anniversaries, but life after my sister’s diagnosis with triple positive breast cancer seems to be full of them. December 1st she found a tumor. December 15th we learned it was cancer. December 17th – her 35th birthday – we learned it was HER2+. December 26th – the fourth anniversary …
All Patients With Metastatic Breast Cancer Should Undergo Germline Testing, Study Finds
By: Laura Joszt From: ajmc.com All patients with metastatic breast cancer should undergo genetic testing, according to a new study on the prevalence of pathogenic/likely pathogenic (P/LP) variants in patients with metastatic breast cancer. The results, published in JAMA Oncology, highlight that there is a high prevalence of P/LP variants among the group of patients with metastatic breast cancer, which could have …
Top 5 Myths About Cancer Clinical Trials
By: Jill Weberding From: medium.com Clinical trials are the only avenue that advances in medicine occur. Every approved drug or treatment must go through the clinical trial process. With the increasing pace of science and technology advances, there were 19 drugs with new approvals for cancer treatment in 2018 according to “CenterWatch” (n.d.). Despite the excitement of tapping into the …
What Influence Do Treatment Costs Have on Breast Cancer Surgery Preferences?
By: Christina Bennett, MS From: cancernetwork.com When deciding about surgery for breast cancer, women, especially those with a lower household income, factored cost of treatment into their decision, according to a study reported in the Journal of Oncology Practice. Julie Nangia, MD, an assistant professor of medicine at the Lester and Sue Breast Center at Baylor College of Medicine, Houston, …
Proton Radiotherapy Safe, Effective for Nonmetastatic Breast Cancer
From: oncnet.com Proton radiotherapy is an effective and safe alternative to conventional radiotherapy, according to results from a phase 2 study of patients with nonmetastatic breast cancer (J Clin Oncol. 2019 Aug 26. Epub ahead of print). Rachel Jiminez, MD, Massachusetts General Hospital, Boston, MA, and colleagues, conducted the phase 2 study with aims to evaluate the safety and efficacy of …
Fewer lymph node operations for breast cancer patients with new prediction models
By: Lund University From: medicalxpress.com In recently published studies, researchers at Lund University and Skåne University Hospital in Sweden have produced new prediction models for improved personalized treatment of lymph nodes in breast cancer patients. The latest results that have now been published in Clinical Cancer Research and BMC Cancer show that up to one in every three operations could …
BRA (Breast Reconstruction Awareness) Day – October 16, 2019
View PostAIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center
Source: ACCESSWIRE From: yahoo.com AIM ImmunoTech Inc., (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases – such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) – announced progress toward the opening of Roswell Park Comprehensive Cancer Center’s Phase 1 clinical study of chemokine modulation plus neoadjuvant chemotherapy in …
20% of women getting lumpectomies need a second surgery, but this risk can be lowered
By: Sheldon Feldman, M.D., F.A.C.S. From: sharsheret.org The lumpectomy procedure (sometimes referred to as Breast Conserving Surgery, or BCS) is the treatment of choice for many people with early-stage breast cancer. The surgeon seeks to remove the malignant tumor, while leaving behind as much healthy breast tissue as possible. Studies show that this procedure, when coupled with radiation, is …
Context Therapeutics and SOLTI launch ONAWA: a Window of Opportunity Study in Breast Cancer with Apristor
Source: Business Wire From: manchestertimes.com Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, today announced a clinical collaboration with SOLTI, a leading collaborative and academic group in Spain dedicated to clinical and translational research in breast cancer. This clinical collaboration, being supported by Context and sponsored by SOLTI, is a window of opportunity study …